 Elizabeth Redente
Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Fibrosis | 15 | 2025 | 400 | 3.680 |
Why?
| | Idiopathic Pulmonary Fibrosis | 14 | 2025 | 653 | 3.070 |
Why?
| | Lung | 26 | 2025 | 4066 | 1.830 |
Why?
| | Bleomycin | 15 | 2025 | 247 | 1.590 |
Why?
| | Macrophages, Alveolar | 8 | 2025 | 392 | 1.460 |
Why?
| | Fibroblasts | 12 | 2025 | 990 | 1.350 |
Why?
| | fas Receptor | 4 | 2020 | 95 | 0.910 |
Why?
| | Alveolar Epithelial Cells | 7 | 2023 | 114 | 0.880 |
Why?
| | Lung Injury | 5 | 2024 | 218 | 0.850 |
Why?
| | Signal Transduction | 11 | 2021 | 5096 | 0.830 |
Why?
| | Lung Diseases | 4 | 2025 | 768 | 0.820 |
Why?
| | Silicosis | 1 | 2023 | 27 | 0.790 |
Why?
| | Collagen | 5 | 2019 | 447 | 0.730 |
Why?
| | Mice | 36 | 2025 | 17843 | 0.700 |
Why?
| | Cytoskeletal Proteins | 1 | 2021 | 156 | 0.690 |
Why?
| | Arthritis, Experimental | 3 | 2018 | 147 | 0.680 |
Why?
| | Lung Diseases, Interstitial | 3 | 2023 | 634 | 0.670 |
Why?
| | Transforming Growth Factor beta | 6 | 2020 | 480 | 0.660 |
Why?
| | Monocytes | 5 | 2023 | 568 | 0.660 |
Why?
| | Animals | 49 | 2025 | 37011 | 0.660 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2020 | 138 | 0.620 |
Why?
| | Respiratory Mucosa | 3 | 2025 | 324 | 0.610 |
Why?
| | Indoles | 2 | 2019 | 415 | 0.580 |
Why?
| | Disease Models, Animal | 13 | 2025 | 4295 | 0.560 |
Why?
| | Cell Separation | 2 | 2019 | 320 | 0.560 |
Why?
| | Epithelial Cells | 4 | 2023 | 1099 | 0.540 |
Why?
| | Macrophages | 8 | 2024 | 1548 | 0.530 |
Why?
| | X-Ray Microtomography | 3 | 2023 | 94 | 0.520 |
Why?
| | Apoptosis | 6 | 2023 | 2557 | 0.510 |
Why?
| | Serum Response Factor | 1 | 2015 | 33 | 0.460 |
Why?
| | Wnt Signaling Pathway | 1 | 2017 | 193 | 0.460 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2024 | 1242 | 0.450 |
Why?
| | Mice, Inbred C57BL | 14 | 2025 | 5792 | 0.450 |
Why?
| | Mesoderm | 1 | 2015 | 144 | 0.430 |
Why?
| | Flow Cytometry | 4 | 2020 | 1185 | 0.430 |
Why?
| | Pneumonia | 4 | 2023 | 638 | 0.390 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2024 | 234 | 0.390 |
Why?
| | Lung Neoplasms | 6 | 2018 | 2494 | 0.390 |
Why?
| | Trans-Activators | 1 | 2015 | 399 | 0.390 |
Why?
| | Cell Polarity | 2 | 2010 | 141 | 0.380 |
Why?
| | Interferon-gamma | 3 | 2010 | 790 | 0.380 |
Why?
| | Lipid Metabolism | 2 | 2025 | 511 | 0.360 |
Why?
| | Disease Progression | 4 | 2025 | 2755 | 0.350 |
Why?
| | Pulmonary Alveoli | 3 | 2025 | 405 | 0.350 |
Why?
| | Mice, Knockout | 10 | 2020 | 3020 | 0.350 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 313 | 0.300 |
Why?
| | Cells, Cultured | 9 | 2020 | 4206 | 0.290 |
Why?
| | Fibrosis | 4 | 2024 | 552 | 0.290 |
Why?
| | Adenoma | 2 | 2007 | 230 | 0.280 |
Why?
| | Receptors, Cell Surface | 1 | 2009 | 391 | 0.280 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 2 | 2020 | 23 | 0.270 |
Why?
| | Urethane | 1 | 2007 | 43 | 0.270 |
Why?
| | Carcinogens | 1 | 2007 | 123 | 0.250 |
Why?
| | Melanoma, Experimental | 2 | 2018 | 113 | 0.240 |
Why?
| | Bone Marrow | 1 | 2007 | 286 | 0.240 |
Why?
| | Humans | 31 | 2025 | 137514 | 0.230 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2007 | 328 | 0.230 |
Why?
| | Lung Compliance | 3 | 2014 | 49 | 0.220 |
Why?
| | Single-Cell Analysis | 3 | 2024 | 309 | 0.220 |
Why?
| | Keratin-8 | 1 | 2023 | 4 | 0.220 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2024 | 17 | 0.220 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2024 | 55 | 0.210 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2024 | 87 | 0.210 |
Why?
| | Cellular Senescence | 1 | 2025 | 188 | 0.210 |
Why?
| | Endoribonucleases | 1 | 2024 | 80 | 0.210 |
Why?
| | Fluorescent Antibody Technique | 2 | 2018 | 386 | 0.210 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2024 | 108 | 0.210 |
Why?
| | Adenocarcinoma | 2 | 2009 | 937 | 0.210 |
Why?
| | Folate Receptor 2 | 1 | 2023 | 9 | 0.200 |
Why?
| | Fibroblast Growth Factor 10 | 2 | 2019 | 23 | 0.200 |
Why?
| | Male | 23 | 2025 | 67718 | 0.200 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2023 | 188 | 0.190 |
Why?
| | Membrane Glycoproteins | 1 | 2024 | 501 | 0.190 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1279 | 0.190 |
Why?
| | Biomarkers | 3 | 2024 | 4172 | 0.190 |
Why?
| | Acute Lung Injury | 2 | 2017 | 288 | 0.180 |
Why?
| | Proline | 1 | 2021 | 80 | 0.170 |
Why?
| | Regeneration | 2 | 2019 | 195 | 0.170 |
Why?
| | Neoplasms, Experimental | 1 | 2020 | 176 | 0.160 |
Why?
| | Multimodal Imaging | 1 | 2020 | 116 | 0.160 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2011 | 654 | 0.160 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 27 | 0.160 |
Why?
| | Interleukin-4 | 2 | 2010 | 217 | 0.160 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2018 | 8 | 0.150 |
Why?
| | Biomedical Research | 1 | 2025 | 689 | 0.150 |
Why?
| | Gene Deletion | 2 | 2018 | 393 | 0.150 |
Why?
| | Mice, Transgenic | 4 | 2019 | 2182 | 0.150 |
Why?
| | Pulmonary Surfactant-Associated Proteins | 1 | 2018 | 10 | 0.150 |
Why?
| | Extracellular Matrix | 2 | 2019 | 528 | 0.150 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2018 | 22 | 0.140 |
Why?
| | CD11 Antigens | 1 | 2018 | 30 | 0.140 |
Why?
| | Adaptive Immunity | 1 | 2018 | 164 | 0.140 |
Why?
| | Lipopolysaccharides | 4 | 2024 | 886 | 0.140 |
Why?
| | Myofibroblasts | 1 | 2018 | 125 | 0.140 |
Why?
| | Imaging, Three-Dimensional | 1 | 2021 | 581 | 0.130 |
Why?
| | Immunoglobulin M | 1 | 2018 | 288 | 0.130 |
Why?
| | Macrophage Activation | 2 | 2009 | 201 | 0.130 |
Why?
| | Homeostasis | 1 | 2020 | 622 | 0.130 |
Why?
| | Phospholipases A2 | 1 | 2016 | 80 | 0.130 |
Why?
| | Lung Diseases, Fungal | 1 | 2016 | 13 | 0.130 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2018 | 379 | 0.130 |
Why?
| | Candida albicans | 1 | 2016 | 56 | 0.130 |
Why?
| | Candidiasis | 1 | 2016 | 57 | 0.130 |
Why?
| | CD11b Antigen | 1 | 2016 | 62 | 0.130 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 62 | 0.130 |
Why?
| | Antigens, Neoplasm | 1 | 2018 | 322 | 0.120 |
Why?
| | Phagocytes | 1 | 2016 | 100 | 0.120 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 277 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1770 | 0.120 |
Why?
| | Dendritic Cells | 1 | 2018 | 488 | 0.120 |
Why?
| | Lipids | 3 | 2024 | 664 | 0.120 |
Why?
| | Neoplasms | 1 | 2010 | 2666 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2021 | 1167 | 0.110 |
Why?
| | Stem Cells | 1 | 2019 | 589 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 806 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2018 | 917 | 0.110 |
Why?
| | Receptor, Macrophage Colony-Stimulating Factor | 1 | 2014 | 11 | 0.110 |
Why?
| | Hydroxyproline | 1 | 2014 | 21 | 0.110 |
Why?
| | Mice, Inbred BALB C | 3 | 2016 | 1271 | 0.110 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2014 | 28 | 0.110 |
Why?
| | Sex Factors | 3 | 2025 | 2074 | 0.110 |
Why?
| | Female | 14 | 2025 | 73162 | 0.110 |
Why?
| | Arthritis, Rheumatoid | 2 | 2013 | 1163 | 0.100 |
Why?
| | Remission Induction | 1 | 2014 | 287 | 0.100 |
Why?
| | Antigens, CD | 1 | 2016 | 524 | 0.100 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2013 | 68 | 0.100 |
Why?
| | Wound Healing | 2 | 2017 | 327 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2018 | 1092 | 0.100 |
Why?
| | Mice, Inbred Strains | 2 | 2010 | 413 | 0.100 |
Why?
| | Delayed-Action Preparations | 1 | 2012 | 180 | 0.090 |
Why?
| | Leukocytes | 1 | 2013 | 311 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 849 | 0.090 |
Why?
| | Chemokine CXCL1 | 1 | 2011 | 76 | 0.090 |
Why?
| | Congresses as Topic | 2 | 2025 | 233 | 0.090 |
Why?
| | Up-Regulation | 2 | 2011 | 846 | 0.090 |
Why?
| | Cytokines | 5 | 2024 | 2095 | 0.090 |
Why?
| | Trauma Severity Indices | 1 | 2011 | 106 | 0.090 |
Why?
| | Pyridones | 1 | 2012 | 168 | 0.090 |
Why?
| | Colonic Neoplasms | 1 | 2013 | 258 | 0.090 |
Why?
| | Neutrophils | 1 | 2016 | 1238 | 0.090 |
Why?
| | Schistosoma mansoni | 1 | 2010 | 37 | 0.080 |
Why?
| | Butylated Hydroxytoluene | 1 | 2010 | 38 | 0.080 |
Why?
| | Schistosomiasis | 1 | 2010 | 47 | 0.080 |
Why?
| | Granuloma | 1 | 2010 | 91 | 0.080 |
Why?
| | Recovery of Function | 1 | 2014 | 662 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 350 | 0.080 |
Why?
| | Sex Characteristics | 2 | 2013 | 766 | 0.080 |
Why?
| | Testosterone | 1 | 2013 | 399 | 0.080 |
Why?
| | Interleukin-13 | 1 | 2010 | 149 | 0.080 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 219 | 0.080 |
Why?
| | Antigens | 1 | 2011 | 358 | 0.080 |
Why?
| | Hepatocyte Growth Factor | 2 | 2019 | 35 | 0.080 |
Why?
| | Intubation, Intratracheal | 1 | 2011 | 259 | 0.070 |
Why?
| | Immunity, Innate | 2 | 2016 | 832 | 0.070 |
Why?
| | Lymph Nodes | 1 | 2011 | 493 | 0.070 |
Why?
| | Societies, Medical | 2 | 2025 | 820 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 920 | 0.070 |
Why?
| | Autoimmunity | 1 | 2013 | 907 | 0.070 |
Why?
| | Angiogenesis Inhibitors | 1 | 2009 | 226 | 0.070 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 301 | 0.070 |
Why?
| | Nanoparticles | 1 | 2012 | 484 | 0.070 |
Why?
| | Tuberculosis | 1 | 2010 | 281 | 0.070 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2007 | 173 | 0.060 |
Why?
| | Survival Rate | 1 | 2011 | 1980 | 0.060 |
Why?
| | Cell Line | 3 | 2019 | 2852 | 0.060 |
Why?
| | Quinazolines | 1 | 2007 | 249 | 0.060 |
Why?
| | Mast Cells | 1 | 2007 | 146 | 0.060 |
Why?
| | Rats | 3 | 2019 | 5676 | 0.060 |
Why?
| | Eye Proteins | 1 | 2024 | 92 | 0.060 |
Why?
| | ErbB Receptors | 1 | 2007 | 616 | 0.050 |
Why?
| | Transcriptome | 2 | 2025 | 974 | 0.050 |
Why?
| | Culture Media, Conditioned | 1 | 2024 | 111 | 0.050 |
Why?
| | Chronic Disease | 1 | 2010 | 1790 | 0.050 |
Why?
| | Wounds and Injuries | 1 | 2010 | 752 | 0.050 |
Why?
| | Age Factors | 1 | 2011 | 3301 | 0.050 |
Why?
| | NADPH Oxidases | 1 | 2024 | 110 | 0.050 |
Why?
| | Time Factors | 1 | 2014 | 6817 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2420 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 2681 | 0.050 |
Why?
| | Phosphorylation | 2 | 2020 | 1762 | 0.050 |
Why?
| | Photoacoustic Techniques | 1 | 2020 | 6 | 0.040 |
Why?
| | Cell Proliferation | 3 | 2017 | 2482 | 0.040 |
Why?
| | Phenotype | 2 | 2019 | 3205 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3292 | 0.040 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 81 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 451 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2018 | 2838 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1740 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 299 | 0.040 |
Why?
| | Research Design | 1 | 2025 | 1116 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 1903 | 0.040 |
Why?
| | Fibroblast Growth Factor 7 | 1 | 2018 | 15 | 0.040 |
Why?
| | CD40 Ligand | 1 | 2018 | 41 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2018 | 2615 | 0.040 |
Why?
| | Culture Media, Serum-Free | 1 | 2018 | 48 | 0.040 |
Why?
| | Scleroderma, Systemic | 1 | 2019 | 122 | 0.040 |
Why?
| | Drug Resistance, Microbial | 1 | 2018 | 71 | 0.040 |
Why?
| | Pulmonary Surfactants | 1 | 2019 | 106 | 0.040 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 77 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 172 | 0.040 |
Why?
| | Antigen-Presenting Cells | 1 | 2018 | 156 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2019 | 146 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2018 | 191 | 0.040 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2018 | 137 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1703 | 0.040 |
Why?
| | Lipogenesis | 1 | 2018 | 60 | 0.040 |
Why?
| | Chemokine CXCL12 | 1 | 2017 | 80 | 0.030 |
Why?
| | Receptors, CXCR4 | 1 | 2017 | 85 | 0.030 |
Why?
| | Permeability | 1 | 2017 | 162 | 0.030 |
Why?
| | Inflammation | 2 | 2023 | 2837 | 0.030 |
Why?
| | Reference Values | 1 | 2018 | 821 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2016 | 120 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2007 | 2145 | 0.030 |
Why?
| | Eicosanoids | 1 | 2016 | 62 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2018 | 621 | 0.030 |
Why?
| | Down-Regulation | 1 | 2018 | 658 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2023 | 1979 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 498 | 0.030 |
Why?
| | Organ Specificity | 1 | 2016 | 304 | 0.030 |
Why?
| | United States | 2 | 2025 | 14696 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2018 | 1150 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2017 | 544 | 0.030 |
Why?
| | Smad Proteins | 1 | 2014 | 42 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2016 | 379 | 0.030 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2014 | 59 | 0.030 |
Why?
| | NIH 3T3 Cells | 1 | 2014 | 144 | 0.030 |
Why?
| | Disease Resistance | 1 | 2013 | 33 | 0.030 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2013 | 45 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2016 | 514 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2014 | 268 | 0.030 |
Why?
| | Adenoviridae | 1 | 2014 | 193 | 0.030 |
Why?
| | Polyglactin 910 | 1 | 2012 | 6 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2013 | 256 | 0.020 |
Why?
| | Bronchoalveolar Lavage | 1 | 2012 | 93 | 0.020 |
Why?
| | Tumor Burden | 1 | 2013 | 311 | 0.020 |
Why?
| | Cell Movement | 1 | 2016 | 972 | 0.020 |
Why?
| | Instillation, Drug | 1 | 2011 | 10 | 0.020 |
Why?
| | Fas Ligand Protein | 1 | 2011 | 59 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 300 | 0.020 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2013 | 235 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1580 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 145 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1505 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3546 | 0.020 |
Why?
| | Smad3 Protein | 1 | 2010 | 43 | 0.020 |
Why?
| | Smad2 Protein | 1 | 2010 | 38 | 0.020 |
Why?
| | Smoke | 1 | 2011 | 144 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 646 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2013 | 682 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2009 | 124 | 0.020 |
Why?
| | Immunoblotting | 1 | 2009 | 307 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3722 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 659 | 0.020 |
Why?
| | Microvessels | 1 | 2009 | 86 | 0.020 |
Why?
| | Injections, Intraperitoneal | 1 | 2007 | 115 | 0.020 |
Why?
| | Erlotinib Hydrochloride | 1 | 2007 | 71 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1227 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1458 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2010 | 1324 | 0.020 |
Why?
| | Silymarin | 1 | 2009 | 199 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1402 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2009 | 208 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2007 | 270 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 7593 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2023 | 15628 | 0.020 |
Why?
| | Aged | 2 | 2018 | 23798 | 0.010 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2010 | 683 | 0.010 |
Why?
| | NF-kappa B | 1 | 2009 | 694 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2857 | 0.010 |
Why?
| | Body Weight | 1 | 2007 | 973 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1775 | 0.010 |
Why?
| | Middle Aged | 2 | 2018 | 33355 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 2066 | 0.010 |
Why?
| | Prospective Studies | 1 | 2011 | 7598 | 0.010 |
Why?
| | Mutation | 1 | 2007 | 3964 | 0.010 |
Why?
|
|
Redente's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|